Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Efficacy and Safety of Inhaled Insulin Compared to Metformin and Glimepiride in Type 2 Diabetes
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2007-05-04
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 174
- Registration Number
- NCT00469586
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Konya, Turkey
Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 Diabetes
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-05-04
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 480
- Registration Number
- NCT00469092
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Stockholm, Sweden
Evaluation of Safety and Efficacy of 17-Beta Estradiol in Treatment of Atrophic Vaginitis: An Extension Trial
Phase 3
Completed
- Conditions
- First Posted Date
- 2007-04-24
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 102
- Registration Number
- NCT00464971
Efficacy and Safety of 17-Beta Estradiol in Treatment of Atrophic Vaginitis
Phase 3
Completed
- Conditions
- First Posted Date
- 2007-04-24
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 230
- Registration Number
- NCT00465192
Evaluation of the Glycaemic Control With Insulin Detemir as an add-on to Current Oral Anti-diabetic Drug Treatment in Subjects With Type 2 Diabetes in Korea
- First Posted Date
- 2007-04-04
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 87
- Registration Number
- NCT00455858
Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-03-14
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 330
- Registration Number
- NCT00447382
Comparison of NPH Insulin and Insulin Detemir in Children and Adolescents With Type 1 Diabetes
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-02-14
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 348
- Registration Number
- NCT00435019
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Norfolk, United Kingdom
Endometrial Safety of a Low Dose of Vagifem® in Postmenopausal Women With Atrophic Vaginitis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-02-05
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 336
- Registration Number
- NCT00431132
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Uppsala, Sweden
Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2007-01-26
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 227
- Registration Number
- NCT00427154
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Tacoma, Washington, United States
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Phase 2
Completed
- Conditions
- First Posted Date
- 2007-01-25
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 400
- Registration Number
- NCT00426803
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Newcastle Upon Tyne, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath